

Salvatore Grisanti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/919883/publications.pdf>

Version: 2024-02-01

51
papers

863
citations

567281

15
h-index

526287

27
g-index

51
all docs

51
docs citations

51
times ranked

1163
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021. <i>Current Opinion in Oncology</i> , 2022, 34, 19-28.	2.4	3
2	Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 797-797.	3.9	1
3	Is adjuvant immunotherapy effective in patients with urothelial cancer?. <i>Minerva Urology and Nephrology</i> , 2022, , .	2.5	0
4	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2167-e2176.	3.6	3
5	Letter to the Editor From Berruti et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	2
6	Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. <i>Endocrinology</i> , 2022, 163, .	2.8	8
7	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	6.3	14
8	Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen. <i>Endocrine</i> , 2022, 77, 438-443.	2.3	7
9	Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 871210.	3.5	5
10	Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 624102.	3.5	7
11	Could a comprehensive urinary endogenous steroidal profile improve the accuracy of prostate-specific antigen screening?. <i>Minerva Urology and Nephrology</i> , 2021, 73, 130-131.	2.5	0
12	Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 651594.	2.4	4
13	Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer. <i>Frontiers in Endocrinology</i> , 2021, 12, 669426.	3.5	15
14	Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2021, 12, 674039.	3.5	5
15	Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor- α . <i>Biomedicines</i> , 2021, 9, 681.	3.2	7
16	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 720748.	4.8	5
17	Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?. <i>Endocrine</i> , 2021, 74, 475-477.	2.3	4
18	Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy. <i>Endocrine</i> , 2021, 72, 20-23.	2.3	1

#	ARTICLE	IF	CITATIONS
19	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 707346.	2.8	1
20	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , 2021, 159, 194-204.	2.8	13
21	Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1-e5.	3.6	22
22	The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. <i>Frontiers in Oncology</i> , 2020, 10, 1574.	2.8	5
23	Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria. <i>Cancers</i> , 2020, 12, 1395.	3.7	7
24	Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies. <i>Journal of Clinical Oncology</i> , 2020, 38, 3363-3366.	1.6	22
25	Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells. <i>Cancers</i> , 2020, 12, 928.	3.7	16
26	Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. <i>Cancers</i> , 2020, 12, 941.	3.7	38
27	Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study. <i>Cancers</i> , 2020, 12, 969.	3.7	3
28	The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma. <i>Future Oncology</i> , 2020, 16, 3017-3020.	2.4	11
29	Is androgen deprivation therapy protective against SARS-CoV-2 infection and related complications in prostate cancer patients?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 778-779.	3.9	3
30	Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 80-87.	1.4	13
31	In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures. <i>Molecular and Cellular Endocrinology</i> , 2019, 498, 110585.	3.2	13
32	Antineoplastic activity of artemisinin in adrenocortical carcinoma. <i>Endocrine</i> , 2019, 66, 425-427.	2.3	3
33	Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	34
34	Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. <i>PLoS ONE</i> , 2019, 14, e0213934.	2.5	7
35	Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy. <i>PLoS ONE</i> , 2019, 14, e0214884.	2.5	13
36	In vitro antitumor activity of progesterone in human adrenocortical carcinoma. <i>Endocrine</i> , 2019, 63, 592-601.	2.3	21

#	ARTICLE	IF	CITATIONS
37	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	3.7	16
38	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	3.7	30
39	Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 458-467.	0.6	22
40	Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma. <i>Endocrine</i> , 2018, 61, 169-172.	2.3	21
41	Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 370-379.	3.9	10
42	Immunotherapy failure in adrenocortical cancer: where next?. <i>Endocrine Connections</i> , 2018, 7, E5-E8.	1.9	39
43	Topoisomerase 2 α and thymidylate synthase expression in adrenocortical cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 319-327.	3.1	24
44	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1358-1365.	3.6	108
45	Systemic Therapy in Locally Advanced or Metastatic Adrenal Cancers: A Critical Appraisal and Clinical Trial Update. <i>European Urology Focus</i> , 2016, 1, 298-300.	3.1	8
46	Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report. <i>AACE Clinical Case Reports</i> , 2016, 2, e337-e341.	1.1	11
47	Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature. <i>Anticancer Research</i> , 2016, 36, 2975-81.	1.1	8
48	EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	39
49	Circulating Tumor Cells in Patients with Recurrent or Metastatic Head and Neck Carcinoma: Prognostic and Predictive Significance. <i>PLoS ONE</i> , 2014, 9, e103918.	2.5	69
50	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121
51	Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 31-34.	0.4	1